本帖最后由 老马 于 2012-1-13 21:20 编辑
$ O0 Z1 g8 F" o) y3 Q+ d7 x1 U2 [
% W( L; K. Q f- U爱必妥和阿瓦斯丁的比较
" E% _' {/ N. J. A& V1 O
: |! H0 D) s h U5 d" H
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
r3 b! o4 E/ L, p U( @* K
+ E0 ]. h5 b9 y' g
7 r6 u! S! q) }
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 f; V# P* Z* ^, e* O; i
==================================================0 c" V( ?) S- h+ V' G( c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) p, R% @+ f- ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* C3 v5 e& s! P4 X* V5 d
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 `" C7 P* Z* O8 U9 U! o9 ~3 o! S
|
显身卡
, I2 S9 x- S _
